

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7068809

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	PARTIAL RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
BANK OF AMERICA, N.A., AS COLLATERAL AGENT	12/01/2021

RECEIVING PARTY DATA

Name:	BIOMAT USA, INC.
Street Address:	2410 LILLYVALE AVENUE
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90032-3514
Name:	TALECRIS PLASMA RESOURCES, INC.
Street Address:	2410 LILLYVALE AVENUE
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90032-3514

PROPERTY NUMBERS Total: 50

Property Type	Number
Patent Number:	5561108
Patent Number:	5688912
Patent Number:	5723579
Patent Number:	5844087
Patent Number:	6037452
Patent Number:	6121422
Patent Number:	5659017
Patent Number:	6566504
Patent Number:	5744586
Patent Number:	6162904
Patent Number:	5561115
Patent Number:	5610285
Patent Number:	5783663
Patent Number:	5831003
Patent Number:	5911165

PATENT

Property Type	Number
Patent Number:	5985836
Patent Number:	6355243
Patent Number:	6462180
Patent Number:	6964764
Patent Number:	6969515
Patent Number:	7544500
Patent Number:	7871608
Patent Number:	8075175
Patent Number:	8231869
Patent Number:	8852585
Patent Number:	8560246
Patent Number:	8101394
Patent Number:	8772461
Patent Number:	8617863
Patent Number:	9206410
Patent Number:	8596326
Patent Number:	9616126
Patent Number:	8759293
Patent Number:	8648177
Patent Number:	8840637
Patent Number:	9121857
Patent Number:	9273366
Patent Number:	9512493
Patent Number:	9879246
Patent Number:	8182808
Patent Number:	9921229
Patent Number:	8034913
Patent Number:	8268782
Patent Number:	8420079
Patent Number:	8512980
Patent Number:	9725501
Patent Number:	10113206
Patent Number:	9290820
Patent Number:	9598739
Application Number:	12741030

CORRESPONDENCE DATA

Fax Number: (202)835-7586

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 202-835-7500
Email: dcip@milbank.com
Correspondent Name: JAVIER J. RAMOS
Address Line 1: 1850 K STREET, NW, SUITE 1100
Address Line 2: MILBANK, LLP
Address Line 4: WASHINGTON, D.C. 20006

ATTORNEY DOCKET NUMBER:	27465.00128
NAME OF SUBMITTER:	JAVIER J. RAMOS
SIGNATURE:	/Javier J. Ramos/
DATE SIGNED:	12/10/2021

Total Attachments: 7

source=Grifols -- Partial Release of Security Interest in Patents (BofA - 2021)#page1.tif
source=Grifols -- Partial Release of Security Interest in Patents (BofA - 2021)#page2.tif
source=Grifols -- Partial Release of Security Interest in Patents (BofA - 2021)#page3.tif
source=Grifols -- Partial Release of Security Interest in Patents (BofA - 2021)#page4.tif
source=Grifols -- Partial Release of Security Interest in Patents (BofA - 2021)#page5.tif
source=Grifols -- Partial Release of Security Interest in Patents (BofA - 2021)#page6.tif
source=Grifols -- Partial Release of Security Interest in Patents (BofA - 2021)#page7.tif

Partial Release of Security Interest in Patents

This **Partial Release of Security Interest in Patents**, dated as of December 1, 2021 (this "Partial Release"), is made by BANK OF AMERICA, N.A., as collateral agent for the Secured Parties (in such capacity, the "Collateral Agent") in favor of BIOMAT USA, INC., a Delaware corporation, and TALECRIS PLASMA RESOURCES, INC., a Delaware corporation (each a "Grantor" and collectively the "Grantors"). For purposes of this Partial Release, the "Secured Parties" shall have the meaning assigned in that certain U.S. Pledge and Security Agreement, dated as of November 15, 2019 entered into by, among others, the Grantors in favor of the Collateral Agent (as amended, restated, or modified from time to time).

WHEREAS, pursuant to that certain Patent Security Agreement, dated as of November 15, 2019 (as amended, restated, or modified from time to time, the "Patent Security Agreement"), the Grantors granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in and continuing lien on all of such Grantors' right, title and interest in, to and under the Patent Collateral (as defined in the Patent Security Agreement), whereby such Patent Security Agreement was recorded with the United States Patent and Trademark Office on November 18, 2019 at Reel 051047 Frame 0123 against those patents and patent applications listed on Schedule I hereto;

WHEREAS, the Grantors have requested that the Collateral Agent release, discharge, terminate and cancel its lien on and security interest (solely to the extent granted by the Grantors) in and to the Patent Collateral (as defined in the Patent Security Agreement) to the extent (if any) owned by the Grantors, including, without limitation, those patents and patent applications listed on Schedule I hereto (the "Released Patent Collateral"); and

WHEREAS, the Patent Security Agreement shall otherwise remain in full force and effect as to all remaining parties to such agreement, including without limitation, as against those patents and patent applications listed on Schedule I hereto;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Collateral Agent, on behalf of the Secured Parties, does hereby consent and agree as follows:

The Collateral Agent, on behalf of the Secured Parties, their successors, legal representatives and assigns, hereby unconditionally and irrevocably (a) releases, discharges, terminates and cancels any and all of its security interest in and to the Released Patent Collateral, (b) agrees that any and all right, title and interest of the Collateral Agent in, to or under the Released Patent Collateral shall hereby terminate, cease and become void, and (c) assigns, transfers and conveys to the Grantors any and all right, title and interest it may have in, to and under the Released Patent Collateral.

The Collateral Agent authorizes and requests that the Commissioner for Patents of the United States Patent and Trademark Office, and any other applicable government officer or authority, record this Partial Release against those patents and patent applications listed on Schedule I hereto.

The Collateral Agent agrees to take all further actions, and provide the Grantors with any information, cooperation and assistance, including, without limitation, the execution and delivery

[Partial Release of Security Interest in Patents]

of any and all further instruments, authorizations, documentation and release forms as any Grantor or its successor, assign or legal representative may reasonably request to confirm, effectuate and record this Partial Release and the termination, cancellation and release of the security interest and any right, title or interest of the Collateral Agent in, to or under the Released Patent Collateral at Grantors' sole cost and expense.


Delivery of an executed signature page of this Partial Release by facsimile or electronic (in pdf or similar format) transmission will be effective as delivery of a manually executed counterpart hereof. The words "execution," "signed," "signature," "delivery," and words of like import in or relating to this Partial Release shall be deemed to include Electronic Signatures (as defined below), deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be. "Electronic Signatures" means any electronic symbol or process attached to, or associated with, any contract or other record and adopted by a person with the intent to sign, authenticate or accept such contract or record.

This Partial Release and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

[Signature page follows]

IN WITNESS WHEREOF, the Collateral Agent has caused this Partial Release to be duly executed and delivered by its officer thereunto duly authorized as of the date hereof.

BANK OF AMERICA, N.A.,
as Collateral Agent

By: 
Name: Angela Larkin
Title: Vice President

Schedule I

PATENT REGISTRATIONS AND APPLICATIONS

Title	Application No.	Filing Date	Patent No. / Pub No.	Issue Date / Pub Date
PREPARATION OF ALPHA-1-ANTICHYMOTRYPSIN	08282860	07/29/1994	5561108	10/01/1996
PEPTIDE LIGANDS WHICH BIND TO VON WILLEBRAND FACTOR	08537069	09/22/1995	5688912	11/18/1997
FIBRINOGEN BINDING PEPTIDES	08595718	02/02/1996	5723579	03/03/1998
METHOD AND DEVICE FOR DELIVERING FIBRIN GLUE	08744488	11/05/1996	5844087	12/01/1998
POLY(ALKYLENE OXIDE)-FACTOR VIII OR FACTOR IX CONJUGATE	07866518	04/10/1992	6037452	03/14/2000
METHOD AND DEVICE FOR DELIVERING FIBRIN GLUE	09200636	11/25/1998	6121422	09/19/2000 ¹
ANION EXCHANGE PROCESS FOR THE PURIFICATION OF FACTOR VIII	08554724	11/7/1995	5,659,017	8/19/1997
PROCESS FOR VIRAL INACTIVATION OF LYOPHILIZED BLOOD PROTEINS	09894346	6/28/2001	6,566,504	5/20/2003
MANUFACTURING PROCESS FOR THE PRODUCTION OF PURIFIED TRANSFERRIN	08668351	6/26/1996	5,744,586	4/28/1998
MANUFACTURING METHOD FOR INTRAVENOUSLY ADMINISTRABLE IMMUNE GLOBULIN AND RESULTANT PRODUCT	09421405	10/21/1999	6,162,904	12/19/2000
LOW TEMPERATURE ALBUMIN FRACTIONATION USING SODIUM CAPRYLATE AS A PARTITIONING AGENT	08288180	8/10/1994	5,561,115	10/1/1996
PURIFICATION OF ALPHA-1 PROTEINASE INHIBITOR USING NOVEL CHROMATOGRAPHIC SEPARATION CONDITIONS	08295119	8/24/1994	5,610,285	3/11/1997
PEPTIDE LIGANDS FOR AFFINITY PURIFICATION OF FIBRINOGEN	09012343	1/23/1998	5,783,663	7/21/1998
PEPTIDES WHICH BIND TO PROTHROMBIN AND THROMBIN	08672805	6/28/1996	5,831,003	11/3/1998

¹ Inventor assignment not recorded.

Title	Application No.	Filing Date	Patent No. / Pub No.	Issue Date / Pub Date
METHOD AND DEVICE FOR MECHANICAL TESTING OF FIBRIN GLUE STRENGTH	08864797	5/29/1997	5,911,165	6/8/1999
ALPHA-1 PROTEINASE INHIBITOR BINDING PEPTIDES	09127574	7/31/1998	5,985,836	11/16/1999
METHOD OF THROMBOLYSIS BY LOCAL DELIVERY OF ACTIVE PLASMIN, PLASMIN FORMULATION AND PROCESS OF PRODUCING	09438331	11/13/1999	6,355,243	3/12/2002
METHOD OF PREPARING ALPHA-1 PROTEINASE INHIBITOR	09449695	11/24/1999	6,462,180	10/8/2002
METHOD OF THROMBOLYSIS BY LOCAL DELIVERY OF REVERSIBLY INACTIVATED ACIDIFIED PLASMIN	10143157	5/10/2002	6,964,764	11/15/2005
METHOD OF THROMBOLYSIS BY LOCAL DELIVERY OF REVERSIBLY ACIDIFIED PLASMIN	10280444	10/25/2002	6,969,515	11/29/2005
PROCESS FOR THE PRODUCTION OF A REVERSIBLY INACTIVE ACIDIFIED PLASMIN COMPOSITION	10692105	10/23/2003	7,544,500	6/9/2009
REVERSIBLY INACTIVATED ACIDIFIED PLASMIN	12197617	8/25/2008	7,871,608	1/8/2011 ²
METHOD FOR MELTING FROZEN, WATER-CONTAINING PRODUCTS IN A MIXER	10579401	2/1/2007	8,075,175	12/13/2011
RECOMBINANT PLASMIN FOR OPHTHALMIC INDICATIONS	12090782	3/23/2009	8,231,869	7/31/2012
METHOD OF TREATMENT AND PROPHYLAXIS OF DISEASES RELATED TO AMYLOID DEPOSITION USING IGM	12162532	5/7/2009	8,852,585	10/7/2014
METHOD COMPOSITION AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN	12741030	9/14/2010	2011000290 9	1/6/2011
METHOD FOR ADJUSTING RESULTS OF A POLYMERASE CHAIN	12742801	9/14/2010	8,560,246	10/15/2013
RECOMBINANTLY MODIFIED PLASMIN	12744376	9/16/2010	8,101,394	1/24/2012
TWO-STAGE ULTRAFILTRATION / DIAFILTRATION	12937454	10/12/2010	8,772,461	7/8/2014
COMPOSITION, METHOD AND KIT FOR PREPARING PLASMIN	12995447	3/18/2011	8,617,863	12/31/2013

² Inventor assignment not recorded.

Title	Application No.	Filing Date	Patent No. / Pub No.	Issue Date / Pub Date
COMPOSITION, METHOD AND KIT FOR PREPARING PLASMINOGEN, AND PLASMIN DERIVED THEREFROM	13147491	9/23/2011	9,206,410	12/8/2015
DEVICE FOR MAINTAINING STERILE INTEGRITY OF CONNECTED FLUID	13262269	12/16/2011	8,596,326	12/3/2013
COMPOSITION, METHOD, AND KIT FOR ALPHA-1 PROTEINASE INHIBITOR	14926450	10/29/2015 ³	9,616,126	4/11/2017
VON WILLEBRAND FACTOR (VWF)-CONTAINING PREPARATIONS, AND METHODS, KITS, AND USES RELATED THERETO	13509309	7/31/2012	8,759,293	6/24/2014
LYOPHILIZATION METHODS, COMPOSITIONS AND KITS	13510401	10/31/2012	8,648,177	2/11/2014
THERAPEUTIC DELIVERY DEVICES, SYSTEMS, AND METHODS	13581697	11/12/2012	8,840,637	9/23/2014
IMMUNOCHROMATOGRAPHY DEVICES, METHODS AND KITS	13823505	3/14/2013	9,121,857	9/1/2015
METHODS, COMPOSITIONS, AND KITS FOR DETERMINING HUMAN IMMUNODEFICIENCY VIRUS (HIV)	14119563	11/22/2013	9,273,366	3/1/2016
COMPOSITIONS, METHODS, AND KITS FOR NUCLEIC ACID HYBRIDIZATION	14237746	6/5/2014	9,512,493	12/6/2016 ⁴
REVERSIBLY INACTIVATED ACIDIFIED PLASMIN COMPOSITION	13761684	2/7/2013	9,879,246	1/30/2018
RECOMBINANTLY MODIFIED PLASMIN	13302322	11/22/2011	8,182,808	5/22/2012 ⁵
IMMUNOCHROMATOGRAPHY DEVICES, METHODS, AND KITS	14803416	7/20/2015 ⁶	9,921,229	3/20/2018
RECOMBINANTLY MODIFIED PLASMIN	11568023	2/1/2008	8,034,913	10/11/2011 ⁷
PROCESS FOR THE PRODUCTION OF A REVERSIBLY INACTIVE ACIDIFIED PLASMIN COMPOSITION	12399438	3/6/2009	8,268,782	9/18/2012 ⁸

³ Inventor assignment not recorded.

⁴ Typo in inventor name in recorded inventor assignment.

⁵ Inventor assignment not recorded.

⁶ Inventor assignment not recorded.

⁷ Inventor assignment not recorded.

⁸ Inventor assignment not recorded.

Title	Application No.	Filing Date	Patent No. / Pub No.	Issue Date / Pub Date
RECOMBINANTLY MODIFIED PLASMIN	13223373	9/1/2011	8,420,079	4/16/2013 ⁹
RECOMBINANTLY MODIFIED PLASMIN	13463437	5/3/2012	8,512,980	8/20/2013 ¹⁰
TWO-STAGE ULTRAFILTRATION/DIAFILTRATION	14294460	6/3/2014 ¹¹	9,725,501	8/8/2017
METHODS, COMPOSITIONS, AND KITS FOR DETERMINING HUMAN IMMUNODEFICIENCY VIRUS (HIV)	14221341	3/21/2014 ¹²	10,113,206	10/30/2018
METHODS FOR DETECTION OF PARVOVIRUS B19	14053245	10/14/2013	9,290,820	3/22/2016 ¹³
HUMAN ERITROVIRUS	14288691	5/28/2014	9,598,739	3/21/2017

⁹ Inventor assignment not recorded.

¹⁰ Inventor assignment not recorded.

¹¹ Inventor assignment not recorded.

¹² Inventor assignment not recorded.

¹³ Inventor assignment not recorded.